163 related articles for article (PubMed ID: 16397246)
1. The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells.
Newman SP; Ireson CR; Tutill HJ; Day JM; Parsons MF; Leese MP; Potter BV; Reed MJ; Purohit A
Cancer Res; 2006 Jan; 66(1):324-30. PubMed ID: 16397246
[TBL] [Abstract][Full Text] [Related]
2. Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause.
Liu ZJ; Lee WJ; Zhu BT
Cancer Res; 2005 Jul; 65(13):5802-11. PubMed ID: 15994956
[TBL] [Abstract][Full Text] [Related]
3. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
[TBL] [Abstract][Full Text] [Related]
4. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Aka JA; Mazumdar M; Lin SX
Mol Cell Endocrinol; 2009 Mar; 301(1-2):183-90. PubMed ID: 19038308
[TBL] [Abstract][Full Text] [Related]
5. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
6. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells.
Brooks JD; Thompson LU
J Steroid Biochem Mol Biol; 2005 Apr; 94(5):461-7. PubMed ID: 15876411
[TBL] [Abstract][Full Text] [Related]
7. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
8. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
Suzuki T; Moriya T; Ariga N; Kaneko C; Kanazawa M; Sasano H
Br J Cancer; 2000 Feb; 82(3):518-23. PubMed ID: 10682658
[TBL] [Abstract][Full Text] [Related]
9. 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique.
Foster PA; Ho YT; Newman SP; Kasprzyk PG; Leese MP; Potter BV; Reed MJ; Purohit A
Breast Cancer Res Treat; 2008 Sep; 111(2):251-60. PubMed ID: 17957467
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
Bydal P; Auger S; Poirier D
Steroids; 2004 May; 69(5):325-42. PubMed ID: 15219411
[TBL] [Abstract][Full Text] [Related]
11. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Gunnarsson C; Olsson BM; Stål O;
Cancer Res; 2001 Dec; 61(23):8448-51. PubMed ID: 11731426
[TBL] [Abstract][Full Text] [Related]
12. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
13. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Smuc T; Rizner TL
Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
[TBL] [Abstract][Full Text] [Related]
14. 17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis.
Nagasaki S; Suzuki T; Miki Y; Akahira J; Kitada K; Ishida T; Handa H; Ohuchi N; Sasano H
Cancer Res; 2009 Feb; 69(4):1392-9. PubMed ID: 19190350
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents.
Ireson CR; Chander SK; Purohit A; Perera S; Newman SP; Parish D; Leese MP; Smith AC; Potter BV; Reed MJ
Br J Cancer; 2004 Feb; 90(4):932-7. PubMed ID: 14970876
[TBL] [Abstract][Full Text] [Related]
16. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
[TBL] [Abstract][Full Text] [Related]
17. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
Jansson AK; Gunnarsson C; Cohen M; Sivik T; Stål O
Cancer Res; 2006 Dec; 66(23):11471-7. PubMed ID: 17145895
[TBL] [Abstract][Full Text] [Related]
18. 17beta-hydroxysteroid dehydrogenases in human breast cancer.
Nagasaki S; Miki Y; Akahira J; Suzuki T; Sasano H
Ann N Y Acad Sci; 2009 Feb; 1155():25-32. PubMed ID: 19250189
[TBL] [Abstract][Full Text] [Related]
19. The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells.
Utsumi T; Leese MP; Chander SK; Gaukroger K; Purohit A; Newman SP; Potter BV; Reed MJ
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):219-27. PubMed ID: 15862969
[TBL] [Abstract][Full Text] [Related]
20. 2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases.
Wood L; Leese MP; Mouzakiti A; Purohit A; Potter BV; Reed MJ; Packham G
Apoptosis; 2004 May; 9(3):323-32. PubMed ID: 15258464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
